Comprehensive disease management for schizophrenia

Peter F Buckley

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

This is a period of rapid development in the pharmacotherapy of schizophrenia. New generation antipsychotic medications appear overall to be more efficacious and better tolerated than the older, conventional antipsychotics. Moreover, these atypical antipsychotics appear to have a broader profile of efficacy which likely includes cognitive effects, possibly antiaggressive effects and the potential to reduce comorbid substance abuse in schizophrenia. Future research efforts are aimed at clarifying the relative profile and potentially broader efficacy of each of these drugs. Future clinical and administrative efforts should focus on availability and access to new treatments, the promulgation of 'best practices' and the articulation and implementation of comprehensive care for persons with schizophrenia. (C) 2000 Prous Science.

Original languageEnglish (US)
Pages (from-to)267-280
Number of pages14
JournalDrugs of Today
Volume36
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Disease Management
Antipsychotic Agents
Schizophrenia
Practice Guidelines
Substance-Related Disorders
Drug Therapy
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Comprehensive disease management for schizophrenia. / Buckley, Peter F.

In: Drugs of Today, Vol. 36, No. 5, 01.01.2000, p. 267-280.

Research output: Contribution to journalReview article

Buckley, Peter F. / Comprehensive disease management for schizophrenia. In: Drugs of Today. 2000 ; Vol. 36, No. 5. pp. 267-280.
@article{0becdc612907411c8a2a4240a2440dbb,
title = "Comprehensive disease management for schizophrenia",
abstract = "This is a period of rapid development in the pharmacotherapy of schizophrenia. New generation antipsychotic medications appear overall to be more efficacious and better tolerated than the older, conventional antipsychotics. Moreover, these atypical antipsychotics appear to have a broader profile of efficacy which likely includes cognitive effects, possibly antiaggressive effects and the potential to reduce comorbid substance abuse in schizophrenia. Future research efforts are aimed at clarifying the relative profile and potentially broader efficacy of each of these drugs. Future clinical and administrative efforts should focus on availability and access to new treatments, the promulgation of 'best practices' and the articulation and implementation of comprehensive care for persons with schizophrenia. (C) 2000 Prous Science.",
author = "Buckley, {Peter F}",
year = "2000",
month = "1",
day = "1",
doi = "10.1358/dot.2000.36.5.575040",
language = "English (US)",
volume = "36",
pages = "267--280",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Comprehensive disease management for schizophrenia

AU - Buckley, Peter F

PY - 2000/1/1

Y1 - 2000/1/1

N2 - This is a period of rapid development in the pharmacotherapy of schizophrenia. New generation antipsychotic medications appear overall to be more efficacious and better tolerated than the older, conventional antipsychotics. Moreover, these atypical antipsychotics appear to have a broader profile of efficacy which likely includes cognitive effects, possibly antiaggressive effects and the potential to reduce comorbid substance abuse in schizophrenia. Future research efforts are aimed at clarifying the relative profile and potentially broader efficacy of each of these drugs. Future clinical and administrative efforts should focus on availability and access to new treatments, the promulgation of 'best practices' and the articulation and implementation of comprehensive care for persons with schizophrenia. (C) 2000 Prous Science.

AB - This is a period of rapid development in the pharmacotherapy of schizophrenia. New generation antipsychotic medications appear overall to be more efficacious and better tolerated than the older, conventional antipsychotics. Moreover, these atypical antipsychotics appear to have a broader profile of efficacy which likely includes cognitive effects, possibly antiaggressive effects and the potential to reduce comorbid substance abuse in schizophrenia. Future research efforts are aimed at clarifying the relative profile and potentially broader efficacy of each of these drugs. Future clinical and administrative efforts should focus on availability and access to new treatments, the promulgation of 'best practices' and the articulation and implementation of comprehensive care for persons with schizophrenia. (C) 2000 Prous Science.

UR - http://www.scopus.com/inward/record.url?scp=0034079730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034079730&partnerID=8YFLogxK

U2 - 10.1358/dot.2000.36.5.575040

DO - 10.1358/dot.2000.36.5.575040

M3 - Review article

VL - 36

SP - 267

EP - 280

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -